© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.
The looming threat of a government shutdown on October 1 may spell potential delays in FDA approvals of new drugs.
Viread (tenofovir) and Epivir (lamivudine) lower the risk of infection with hepatitis B among HIV-positive gay men who haven’t been vac...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
